Showing 13 to 13 of 13 results
faz.net
🌐 85% Global Worthiness
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Injectable HIV PrEP Shows 96% Infection Reduction
Lenacapavir, a new injectable HIV PrEP medication, demonstrated 96% infection reduction compared to daily Truvada in clinical trials, offering improved convenience and addressing stigma, though high cost remains a concern.
Progress
48% Bias Score
Showing 13 to 13 of 13 results